"While Optos and Spectralis are comparable for measuring GA in clinical trials and patient monitoring, the two modalities are not interchangeable. Clinicians and researchers should stick to one ...
Shares in Optos gain 3.4 percent as the medical products firm receives U.S. Food and Drug Administration clearance to market its Daytona Device, the company's next-generation ultra-wide field retinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results